Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
RCT (n=202) reports sorafenib maintenance post-transplantation can reduce relapse and is well tolerated in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation.
Source:
The Lancet Oncology
SPS commentary:
The 1-year cumulative incidence of relapse was 7.0% (95% CI 3.1–13.1) in the sorafenib group and 24.5% (16.6–33.2) in the control group (i.e. no maintenance with sorafenib group); hazard ratio 0.25, 95% CI 0.11–0.57; p=0.0010).
Authors of a related commentary state this strategy could be a suitable therapeutic option for patients with FLT3-ITD acute myeloid leukaemia.